Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.6
Commitments and Contingencies (Details Textual) (USD $)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 29, 2012
Oct. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Mar. 31, 2009
Nov. 30, 2008
Sep. 30, 2008
Jun. 30, 2007
Jul. 30, 2006
Mar. 31, 2006
Jun. 30, 2012
Sep. 30, 2009
Aug. 31, 2009
Mar. 22, 2006
Jun. 30, 2012
Chem Master Agreement [Member]
Jun. 30, 2011
Chem Master Agreement [Member]
Jun. 30, 2012
Chem Master Agreement [Member]
Jun. 30, 2011
Chem Master Agreement [Member]
Jun. 30, 2012
Agreement With Ascentage Pharma Group [Member]
Jun. 30, 2012
Agreements With Ash Stevens [Member]
Jun. 30, 2012
Master Laboratory Services Agreement With Wil Research Laboratories [Member]
Jun. 30, 2012
Consulting Arrangements [Member]
May 21, 2012
Consulting Arrangements [Member]
Oct. 15, 2011
Consulting Arrangements [Member]
Apr. 15, 2011
Consulting Arrangements [Member]
Feb. 18, 2011
Consulting Arrangements [Member]
Oct. 15, 2010
Consulting Arrangements [Member]
Apr. 15, 2010
Consulting Arrangements [Member]
Apr. 07, 2010
Consulting Arrangements [Member]
Cooperative Research and Development Agreement Description and Terms                   The CRADA was for a term of 74 months from the effective date and can be unilaterally terminated by either party by providing written notice within 60 days.                                      
Cooperative Research and Development Project Commitments, Amount                     $ 50,000 $ 200,000 $ 100,000 $ 200,000                              
Cooperative Research Commitments Due, Current                           200,000                              
Payments To Fund Cooperative Research and Development 25,000 25,000 50,000 50,000 50,000   50,000 200,000 200,000                                        
National Institute Of Health Patent License Agreement, Terms             The PLA provided for an initial payment of $25,000 to the NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated.                                            
Patent License Agreement, Minimum Annual Royalty, Amount                     30,000                                    
Payments To National Institute Of Health Patent License Agreement Initial Payment           25,000                                              
Research and Development Contract, Estimated Cost, Various Clinical Studies                                     23,840 62,000 160,740                
Research and Development Contract, Payments For Various Clinical Studies                                     14,304 53,240 93,090                
Annual Fee Payable, Clinical Trial                                                         25,000
Annual Fee Payable, Clinical Trial, Installment Amount                                                     12,500 12,500  
Additional Annual Fee Payable, Clinical Trial                                             25,000     25,000      
Additional Annual Fee Payable, Clinical Trial, Installment Amount                                           12,500 12,500 12,500 12,500        
Principal Cash Obligations and Commitments, Current                     243,903                                    
Cost Of Materials Labor And Expenses                             0 1,500 0 6,325                      
Principal Cash Obligations and Commitments                     $ 385,163